EcoR1 Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

EcoR1 Capital’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-66,978	Closed	-$1.21M	–	54
2023 Q2	$1.21M	Buy	+66,978	New	+$1.23M	0.03%	48

Other funds holding FDMT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital's FDMT Position: Q3 2023 in Review

EcoR1 Capital sold out of 4D Molecular Therapeutics (FDMT) in Q3 2023, closing a stake of 66,978 shares — an estimated $1.21M sold.

EcoR1 Capital first reported a position in FDMT in Q2 2023 and held it in 1 quarter. The position peaked at $1.21M in Q2 2023. 110 funds tracked by Wall St. Rank hold FDMT as of Q3 2023.

EcoR1 Capital reported no remaining 4D Molecular Therapeutics position as of Q3 2023 after selling out during the quarter.
EcoR1 Capital sold 66,978 4D Molecular Therapeutics shares in Q3 2023, an estimated $1.21M.
EcoR1 Capital first reported a position in 4D Molecular Therapeutics in Q2 2023 and held it in 1 quarter.
EcoR1 Capital's 4D Molecular Therapeutics position peaked at $1.21M in Q2 2023.
110 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2023.

Based on EcoR1 Capital's 13F filing for Q3 2023, filed 14 Nov 2023.